Verrica Pharmaceuticals Net Worth
Verrica Pharmaceuticals Net Worth Breakdown | VRCA |
Verrica Pharmaceuticals Net Worth Analysis
Verrica Pharmaceuticals' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Verrica Pharmaceuticals' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Verrica Pharmaceuticals' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Verrica Pharmaceuticals' net worth analysis. One common approach is to calculate Verrica Pharmaceuticals' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Verrica Pharmaceuticals' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Verrica Pharmaceuticals' net worth. This approach calculates the present value of Verrica Pharmaceuticals' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Verrica Pharmaceuticals' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Verrica Pharmaceuticals' net worth. This involves comparing Verrica Pharmaceuticals' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Verrica Pharmaceuticals' net worth relative to its peers.
Enterprise Value |
|
To determine if Verrica Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Verrica Pharmaceuticals' net worth research are outlined below:
| Verrica Pharmaceuticals generated a negative expected return over the last 90 days | |
| Verrica Pharmaceuticals has high historical volatility and very poor performance | |
| Verrica Pharmaceuticals may become a speculative penny stock | |
| Verrica Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 5.12 M. Net Loss for the year was (67 M) with profit before overhead, payroll, taxes, and interest of 8.31 M. | |
| Verrica Pharmaceuticals currently holds about 14.4 M in cash with (38.58 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.35. | |
| Verrica Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Roughly 44.0% of the company outstanding shares are owned by insiders | |
| Latest headline from thelincolnianonline.com: Propel Bio Management LLC Has 500,000 Stake in Verrica Pharmaceuticals Inc. |
Verrica Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Verrica Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Verrica Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Verrica Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Verrica Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Verrica Pharmaceuticals backward and forwards among themselves. Verrica Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Verrica Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Exoduspoint Capital Management, Lp | 2024-09-30 | 186.1 K | Deutsche Bank Ag | 2024-06-30 | 182 K | Bml Capital Management Llc | 2024-09-30 | 180 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 169.9 K | Renaissance Technologies Corp | 2024-09-30 | 148 K | Wellington Management Company Llp | 2024-06-30 | 119.9 K | Two Sigma Investments Llc | 2024-09-30 | 115.3 K | Steel Peak Wealth Management Llc | 2024-09-30 | 102 K | Kovitz Investment Group Partners, Llc | 2024-06-30 | 100.1 K | Perceptive Advisors Llc | 2024-09-30 | 7.1 M | Vanguard Group Inc | 2024-09-30 | 1.3 M |
Follow Verrica Pharmaceuticals' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 115.92 M.Market Cap |
|
Project Verrica Pharmaceuticals' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.82) | (0.86) | |
| Return On Capital Employed | (1.02) | (1.07) | |
| Return On Assets | (0.82) | (0.86) | |
| Return On Equity | (3.39) | (3.22) |
When accessing Verrica Pharmaceuticals' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Verrica Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Verrica Pharmaceuticals' profitability and make more informed investment decisions.
Please note, the presentation of Verrica Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Verrica Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Verrica Pharmaceuticals' management manipulating its earnings.
Evaluate Verrica Pharmaceuticals' management efficiency
Verrica Pharmaceuticals has return on total asset (ROA) of (0.7141) % which means that it has lost $0.7141 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (20.5989) %, meaning that it created substantial loss on money invested by shareholders. Verrica Pharmaceuticals' management efficiency ratios could be used to measure how well Verrica Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of December 1, 2024, Return On Tangible Assets is expected to decline to -0.86. In addition to that, Return On Capital Employed is expected to decline to -1.07. At present, Verrica Pharmaceuticals' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 3.9 M, whereas Total Assets are forecasted to decline to about 62 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.44 | 0.41 | |
| Tangible Book Value Per Share | 0.44 | 0.41 | |
| Enterprise Value Over EBITDA | (4.95) | (5.20) | |
| Price Book Value Ratio | 16.79 | 17.63 | |
| Enterprise Value Multiple | (4.95) | (5.20) | |
| Price Fair Value | 16.79 | 17.63 | |
| Enterprise Value | 307.9 M | 283.5 M |
Verrica Pharmaceuticals showcases strong leadership that adapts to market changes and drives innovation. Our analysis explores how this adaptability affects the stock's investment appeal.
Enterprise Value Revenue 15.2092 | Revenue 9.2 M | Quarterly Revenue Growth 27.445 | Revenue Per Share 0.198 | Return On Equity (20.60) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Verrica Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Verrica Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Verrica Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Verrica Pharmaceuticals time-series forecasting models is one of many Verrica Pharmaceuticals' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Verrica Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Verrica Pharmaceuticals Earnings per Share Projection vs Actual
Verrica Pharmaceuticals Corporate Management
| Eugene Scavola | Executive Operations | Profile | |
| Terence Kohler | Chief Officer | Profile | |
| Dr MBA | Head Development | Profile | |
| Christopher Hayes | Secretary, Officer | Profile | |
| Joe Bonaccorso | Chief Commercial Officer | Profile | |
| Gary MD | Chief Officer | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Verrica Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade Verrica Stock refer to our How to Trade Verrica Stock guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Verrica Pharmaceuticals. If investors know Verrica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Verrica Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.84) | Revenue Per Share 0.198 | Quarterly Revenue Growth 27.445 | Return On Assets (0.71) | Return On Equity (20.60) |
The market value of Verrica Pharmaceuticals is measured differently than its book value, which is the value of Verrica that is recorded on the company's balance sheet. Investors also form their own opinion of Verrica Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Verrica Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Verrica Pharmaceuticals' market value can be influenced by many factors that don't directly affect Verrica Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Verrica Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Verrica Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Verrica Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.